NO2951201T3 - - Google Patents

Info

Publication number
NO2951201T3
NO2951201T3 NO14702547A NO14702547A NO2951201T3 NO 2951201 T3 NO2951201 T3 NO 2951201T3 NO 14702547 A NO14702547 A NO 14702547A NO 14702547 A NO14702547 A NO 14702547A NO 2951201 T3 NO2951201 T3 NO 2951201T3
Authority
NO
Norway
Application number
NO14702547A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2951201T3 publication Critical patent/NO2951201T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO14702547A 2013-02-08 2014-01-30 NO2951201T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13154552 2013-02-08
EP13187265 2013-10-03

Publications (1)

Publication Number Publication Date
NO2951201T3 true NO2951201T3 (de) 2018-03-17

Family

ID=51261487

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14702547A NO2951201T3 (de) 2013-02-08 2014-01-30

Country Status (14)

Country Link
US (1) US9593157B2 (de)
EP (1) EP2951201B1 (de)
JP (1) JP6443344B2 (de)
CN (2) CN105102478A (de)
AU (1) AU2014211355B2 (de)
CA (1) CA2899693C (de)
DK (1) DK2951201T3 (de)
ES (1) ES2654675T3 (de)
HR (1) HRP20171777T1 (de)
HU (1) HUE035315T2 (de)
NO (1) NO2951201T3 (de)
PL (1) PL2951201T3 (de)
PT (1) PT2951201T (de)
WO (1) WO2014118297A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118297A1 (en) 2013-01-30 2014-08-07 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
AU2014214054B2 (en) * 2013-02-05 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Muscarinic acetylcholine receptor binding agents and uses thereof
JP6687525B2 (ja) 2014-01-30 2020-04-22 ブイアイビー ブイゼットダブリュVib Vzw オピオイド受容体結合剤およびその使用
US10995361B2 (en) 2017-01-23 2021-05-04 Massachusetts Institute Of Technology Multiplexed signal amplified FISH via splinted ligation amplification and sequencing
WO2018157048A1 (en) 2017-02-24 2018-08-30 Massachusetts Institute Of Technology Methods for examining podocyte foot processes in human renal samples using conventional optical microscopy
WO2018157074A1 (en) 2017-02-24 2018-08-30 Massachusetts Institute Of Technology Methods for diagnosing neoplastic lesions
CN106908610B (zh) * 2017-03-13 2018-11-02 绍兴康知生物科技有限公司 一种基于受体配体结合技术筛查吸食吗啡的试剂、制备方法及应用
US11180804B2 (en) 2017-07-25 2021-11-23 Massachusetts Institute Of Technology In situ ATAC sequencing
US11293923B2 (en) 2017-09-01 2022-04-05 Massachusetts Institute Of Technology S-layer protein 2D lattice coupled detergent-free GPCR bioelectronic interfaces, devices, and methods for the use thereof
EP3704160A1 (de) * 2017-10-31 2020-09-09 VIB vzw Neuartige antigenbindende chimäre proteine und verfahren und verwendungen davon
WO2019156957A1 (en) 2018-02-06 2019-08-15 Massachusetts Institute Of Technology Swellable and structurally homogenous hydrogels and methods of use thereof
CA3124790A1 (en) * 2019-01-09 2020-07-16 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses
CN109856393A (zh) * 2019-04-16 2019-06-07 浙江诺迦生物科技有限公司 一种基于细胞多巴胺释放效应的阿片类活性物质的检测方法及其检测试剂盒
US20220276244A1 (en) 2019-04-29 2022-09-01 Confo Therapeutics N.V. Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs
US11802822B2 (en) 2019-12-05 2023-10-31 Massachusetts Institute Of Technology Multiplexed expansion (MultiExM) pathology
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
EP4035677A1 (de) * 2021-01-28 2022-08-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Faltungspromotoren und ihre verwendung zur herstellung und stabilisierung von polypeptiden

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (de) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
OA11862A (en) 1999-04-22 2006-03-02 Unilever Nv Inhibition of viral infection using monovalent antigen-binding proteins.
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
EP1233987B1 (de) 1999-11-29 2009-08-19 Bac Ip B.V. Immobilisierte antigenbindende moleküle aus einer domäne
ES2275563T3 (es) 1999-11-29 2007-06-16 Unilever N.V. Inmovilizacion de proteinas mediante el uso de un segmento polipeptidico.
EP1134231B1 (de) 2000-03-14 2009-04-15 Unilever N.V. Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
WO2002048193A2 (en) 2000-12-13 2002-06-20 Unilever N.V. Camelidae antibody arrays
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
WO2004035614A1 (en) 2001-07-11 2004-04-29 Karo Bio Ab Synthetic or partially purified peptides which can bind to specific subunits of g proteins and uses thereof
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) 可変領域配列のクローニング方法
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
EP2336179A1 (de) 2002-11-08 2011-06-22 Ablynx N.V. Stabilisierte Einzel-Domäne-Antikörper
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
EP2390270A1 (de) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutische Polypeptide, Homologe davon, Fragmente davon und Verwendung bei modulierender plättchenvermittelter Aggregation
EP2251357A1 (de) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae schweren Ketten Antikörpern VHHS gegen Epidermal Growth Faktor Rezeptor (EGFR) und Ihre Verwendungen
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
EP1844073A1 (de) 2005-01-31 2007-10-17 Ablynx N.V. Verfahren zur erzeugung von sequenzen der variablen domäne von antikörpern mit schweren ketten
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
US7807162B2 (en) 2005-05-20 2010-10-05 Ablynx N.V. Single domain VHH antibodies against von Willebrand factor
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
JP2010518839A (ja) 2007-02-21 2010-06-03 アブリンクス エン.ヴェー. 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び/もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
CA2681415C (en) 2007-03-22 2020-11-03 Heptares Therapeutics Limited Mutant g-protein coupled receptors and methods for selecting them
KR20120125601A (ko) 2007-05-24 2012-11-16 아블린쓰 엔.브이. Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
US7947807B2 (en) 2007-10-15 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3)
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) * 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
US20110294983A1 (en) 2008-12-08 2011-12-01 Complix Nv Single-chain antiparallel coiled coil proteins
DE112009003718T5 (de) * 2008-12-10 2012-09-06 Universiteit Antwerpen Rasteruntersuchungsverfahren zur Identifizierung von Genen, die am Zellzyklus beteiligt sind
AU2009329501B2 (en) 2008-12-19 2015-11-26 Ablynx N.V. Genetic immunization for producing immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4
BRPI1006998A2 (pt) * 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
WO2011042398A1 (en) * 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
WO2012030735A1 (en) 2010-08-30 2012-03-08 Confometrx, Inc. Method and composition for crystallizing a family c gpcr
DE102010051090A1 (de) * 2010-11-12 2012-05-31 Carsten Malcher Suspension zum Auftragen auf Sportgeräte
US20140031525A1 (en) 2011-01-21 2014-01-30 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
WO2012148586A1 (en) 2011-03-15 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Gpcr fusion protein containing an n-terminal autonomously folding stable domain, and crystals of the same
WO2012158555A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Novel fusion partners for the purpose of crystallizing g-protein coupled receptors
US8835362B2 (en) * 2012-12-26 2014-09-16 International Business Machines Corporation Modifying single proteins (GPCR), ligands, and nanopore surfaces to create binding-induced molecular changes of protein-ligand complexes detected in nanochannel translocation
WO2014118297A1 (en) 2013-01-30 2014-08-07 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes

Also Published As

Publication number Publication date
EP2951201B1 (de) 2017-10-18
HRP20171777T1 (hr) 2017-12-29
AU2014211355B2 (en) 2017-07-13
WO2014118297A1 (en) 2014-08-07
AU2014211355A1 (en) 2015-08-06
ES2654675T3 (es) 2018-02-14
CN105102478A (zh) 2015-11-25
CN112858672A (zh) 2021-05-28
CA2899693C (en) 2023-03-14
EP2951201A1 (de) 2015-12-09
US20150376261A1 (en) 2015-12-31
PT2951201T (pt) 2018-01-09
CA2899693A1 (en) 2014-08-07
US9593157B2 (en) 2017-03-14
DK2951201T3 (en) 2018-01-08
HUE035315T2 (en) 2018-05-02
PL2951201T3 (pl) 2018-03-30
JP6443344B2 (ja) 2018-12-26
JP2016504919A (ja) 2016-02-18

Similar Documents

Publication Publication Date Title
BR112016011719A2 (de)
BR112016000832A2 (de)
BR112014017733A2 (de)
BR112014018502A2 (de)
BR112014017739A2 (de)
BR112014019326A2 (de)
BR112014017855A2 (de)
BR112014020341A2 (de)
BR112014018480A2 (de)
BR112014017765A2 (de)
BR112014021878A2 (de)
BR112016008659A2 (de)
BR112016005705A2 (de)
BR112014017901A2 (de)
NO2951201T3 (de)
BR112014018207A2 (de)
BR112014019204A2 (de)
BR112016008415A2 (de)
BR112015015948A2 (de)
BR112014018483A2 (de)
BR112014017794A2 (de)
BR112016010556A2 (de)
BR112014017601A2 (de)
BR112015015312A2 (de)
BR112014018353A2 (de)